302 related articles for article (PubMed ID: 3104456)
21. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection.
Ahuja SS; Reddick RL; Sato N; Montalbo E; Kostecki V; Zhao W; Dolan MJ; Melby PC; Ahuja SK
J Immunol; 1999 Oct; 163(7):3890-7. PubMed ID: 10490989
[TBL] [Abstract][Full Text] [Related]
22. IL-12 is essential for resistance against Yersinia enterocolitica by triggering IFN-gamma production in NK cells and CD4+ T cells.
Bohn E; Autenrieth IB
J Immunol; 1996 Feb; 156(4):1458-68. PubMed ID: 8568248
[TBL] [Abstract][Full Text] [Related]
23. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
[TBL] [Abstract][Full Text] [Related]
24. Macrophage activation by interferon-gamma from host-protective T cells is inhibited by interleukin (IL)3 and IL4 produced by disease-promoting T cells in leishmaniasis.
Liew FY; Millott S; Li Y; Lelchuk R; Chan WL; Ziltener H
Eur J Immunol; 1989 Jul; 19(7):1227-32. PubMed ID: 2503386
[TBL] [Abstract][Full Text] [Related]
25. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
26. Parasite accessory cell interactions in murine leishmaniasis. I. Evasion and stimulus-dependent suppression of the macrophage interleukin 1 response by Leishmania donovani.
Reiner NE
J Immunol; 1987 Mar; 138(6):1919-25. PubMed ID: 3493291
[TBL] [Abstract][Full Text] [Related]
27. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
28. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection.
Melby PC; Tabares A; Restrepo BI; Cardona AE; McGuff HS; Teale JM
Exp Parasitol; 2001 Sep; 99(1):17-25. PubMed ID: 11708830
[TBL] [Abstract][Full Text] [Related]
29. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
30. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
Bretscher PA; Ogunremi O; Menon JN
Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
[TBL] [Abstract][Full Text] [Related]
31. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
Nabors GS; Farrell JP
Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
[TBL] [Abstract][Full Text] [Related]
32. Leishmania infantum: soluble proteins released by the parasite exert differential effects on host immune response.
Rosa R; Rodrigues OR; Marques C; Santos-Gomes GM
Exp Parasitol; 2005 Feb; 109(2):106-14. PubMed ID: 15687017
[TBL] [Abstract][Full Text] [Related]
33. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis.
Oliveira-Freitas E; Casas CP; Borja-Cabrera GP; Santos FN; Nico D; Souza LO; Tinoco LW; da Silva BP; Palatnik M; Parente JP; Palatnik-de-Sousa CB
Vaccine; 2006 May; 24(18):3909-20. PubMed ID: 16556475
[TBL] [Abstract][Full Text] [Related]
34. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
35. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
36. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
[TBL] [Abstract][Full Text] [Related]
37. Innate immune defense in visceral leishmaniasis: cytokine mediated protective role by allogeneic effector cell.
Manna PP; Chakrabarti G; Bandyopadhyay S
Vaccine; 2010 Jan; 28(3):803-10. PubMed ID: 19879234
[TBL] [Abstract][Full Text] [Related]
38. Production of interleukin 3 and gamma-interferon by an antigen-specific mouse suppressor T cell clone.
Koyasu S; Nakauchi H; Kitamura K; Yonehara S; Okumura K; Tada T; Yahara I
J Immunol; 1985 May; 134(5):3130-6. PubMed ID: 2580015
[TBL] [Abstract][Full Text] [Related]
39. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.
Pinelli E; Gonzalo RM; Boog CJ; Rutten VP; Gebhard D; del Real G; Ruitenberg EJ
Eur J Immunol; 1995 Jun; 25(6):1594-600. PubMed ID: 7614987
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
Henriquez FL; Campbell SA; Roberts CW; Mullen AB; Burchmore R; Carter KC
J Parasitol; 2010 Oct; 96(5):929-36. PubMed ID: 20950100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
